Work

A study of intense neoadjuvant testosterone lowering therapy with goserelin and enzalutamide (Enza) in high-risk prostate cancer (PC) with multiparametric MRI (mpMRI).

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.7_suppl.63

Authors: Fatima Karzai, Ravi Amrit Madan, David James VanderWeele, Guinevere Chun, Marijo Bilusic, Lisa M. Cordes, Nicole Carrabba, Scott Wilkinson, Huihui Ye, Stephanie Harmon, Adam G. Sowalsky, Baris Turkbey, Peter A. Pinto, Peter L. Choyke, James L. Gulley, William L. Dahut

Institutions: National Institutes of Health, National Cancer Institute, Beth Israel Deaconess Medical Center, Leidos Biomedical Research Inc. (United States)

Language: English

Topic: Prostate Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2921880439

Cites:

Cited by: 1

Related to: 10